不良病理特征对复发性前列腺癌术后放疗联合激素治疗潜在获益的影响:个体患者数据荟萃分析
该个体患者数据荟萃分析纳入5项随机3期试验的4781例患者,中位随访9.1年,评估不良病理特征计数(AFC)是否改变术后放疗联合激素治疗(HT)的总生存(OS)和无转移生存(MFS)获益。结果显示AFC对OS获益(交互HR 0.93,95%CI 0.79-1.10,p=0.4)和MFS获益(交互HR 0.88,95%CI 0.77-1.01,p=0.08)均无显著修饰作用。结论提示不良病理特征具预后价值但不预测HT获益。
要点
- AFC是OS和MFS的独立预后因素,但不显著改变HT的OS或MFS获益。
- 在放疗前PSA≤0.5 ng/ml患者中,不良病理特征不预测HT获益。
- 分类分析和高危亚组分析结果与主分析一致。
核心结论
- 不良病理特征虽具预后价值,但不预测术后放疗联合HT的获益。
- 该结论适用于放疗前PSA≤0.5 ng/ml的患者。
研究设计与样本
- 个体患者数据荟萃分析,纳入5项随机3期试验的4781例患者,中位随访9.1年。
- AFC前瞻性定义为Grade Group 4-5、精囊侵犯、切缘阳性、包膜外侵犯之和(0-4分)。
- 采用意向性治疗的单阶段荟萃分析模型。
主要发现
- AFC对OS获益的交互HR为0.93(95%CI 0.79-1.10,p=0.4)。
- AFC对MFS获益的交互HR为0.88(95%CI 0.77-1.01,p=0.08)。
- AFC分类分析、高危亚组分析及限制性AFC评分(仅GG4-5和精囊侵犯,0-2分)结果相似。
临床怎么用
- 对于放疗前PSA≤0.5 ng/ml的复发性前列腺癌患者,不应仅凭不良病理特征数量选择是否联合HT。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: A recent individual patient data (IPD) meta-analysis of randomized trials found a limited overall survival (OS) and metastasis-free survival (MFS) benefit to the addition of hormonal therapy (HT) to postoperative radiotherapy for prostate cancer in patients with pre-radiotherapy prostate-specific antigen (PSA) ≤0.5 ng/ml. We evaluated whether the OS and MFS benefits of adding HT might be significantly modified by an increasing count of adverse pathological features (adverse feature count [AFC]). METHODS: We obtained IPD from five randomized phase 3 trials of postoperative radiotherapy ± HT. AFC was prospectively defined as the sum (0-4) of grade group 4-5 disease, seminal vesicle invasion, positive surgical margins, and extracapsular extension. Intention-to-treat one-stage meta-analytical models were used. We also evaluated the interaction of the benefit of HT with a restricted score comprising only GG4-5 and seminal vesicle invasion (range 0-2), as a pre-specified sensitivity analysis. KEY FINDINGS AND LIMITATIONS: We included IPD from 4781 patients with a median follow-up of 9.1 yr. AFC was independently prognostic for OS and MFS. However, AFC did not significantly modify the OS benefit of HT (interaction hazard ratio [HR], 0.93; 95% confidence interval [CI], 0.79-1.10; p = 0.4) or MFS benefit (interaction HR, 0.88; 95% CI, 0.77-1.01; p = 0.08). Results were similar when AFC was analyzed categorically and in high-risk subsets, and when the restricted AFC score was used. CONCLUSIONS AND CLINICAL IMPLICATIONS: Overall, the data suggest that although adverse pathological features are prognostic, they do not appear predictive of HT benefit after postoperative radiotherapy, which is relevant for patients with a PSA ≤0.5 ng/ml before radiation.
引用
- Kishan AU, Sun Y, Parker CC, et al. Influence of Adverse Pathologic Features on Potential Benefit of Hormone Therapy Use with Postoperative Radiotherapy in Recurrent Prostate Cancer: An Individual Patient Data Meta-analysis. Eur Urol. 2026. PMID: 42521517. doi:10.1016/j.eururo.2026.07.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。